|Table of Contents|

Modified CHOPE regimen on the outcome of malignant lymphoma with EBV infection

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 06
Page:
928-931
Research Field:
Publishing date:

Info

Title:
Modified CHOPE regimen on the outcome of malignant lymphoma with EBV infection
Author(s):
Gu Liufang; Feng Yuandong; Cui Xiaoguang; He Aili; Zhang Wanggang; Cao Xingmei
Department of Hematology,the Second Affiliated Hospital of Xi'an Jiaotong University,Shaanxi Xi'an 710004,China.
Keywords:
EB virus; malignant lymphoma; modified CHOPE regimen; rate survival
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2018.06.028
Abstract:
Objective:To observe the clinical efficacy and side effects of modified CHOPE regimen in the treatment of EBV positive malignant lymphoma.Methods:In this study,46 patients with EBV positive lymphoma were treated with modified CHOPE regimen combined with antiviral and local radiotherapy.Results:21 cases(complete remission rate 45.7%) achieved complete remission,12 cases(partial remission rate of 26.1%) achieved partial remission,stable state in 8 cases and 5 cases of disease progression,the total effective rate was 71.7%.After treatment,the total effective rate was 81.2%.The 1 year overall survival rate was 78%,the 1 year disease-free survival rate was 69%,the 3 years overall survival rate was 34.7%,and the 3 years disease-free survival rate was 31%.Conclusion:Modified regimen CHOPE is effective in the treatment of lymphoma with EBV positive.The side effects can be safe and well tolerated,but long-term survival is still poor.So allogeneic peripheral blood stem cell transplantation should be taken into consideriation in malignant lymphoma with EBV to obtain a long- term survival.

References:

[1] Grivennikov SI,Greten FR,Karin M.Immunity,inflammation,and cancer［J］.Cell,2010,140:883-899.
[2] Butel JS.Viral carcinogenesis:Revelation of molecular mechanisms and etiology of human disease［J］.Carcinogenesis,2000,21:405-426.
[3]Thompson MP,Kurzrock R.Epstein-Barr virus and cancer［J］.Clin Cancer Res,2004,10:803-821.
[4]Young LS,Rickinson AB.Epstein-Barr virus:40 years on［J］.Nat Rev Cancer,2004,4:757-768.
[5]Huang Huiqiang,Wang Xiaoxiao.Progress in the treatment of NK/T cell lymphoma［J］.Journal of Acute Critical Illness,2008,14(1):11-13.
[6]Lister TA，Crowther D，Sutcliffe SB，et al.Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease:Cotswolds meeting［J］.J Clin Oncol,1989,7(11):1630-1636.
[7]Cheson BD,Pfistner B,Juweid ME,et al.Revised response criteria for malignant lymphoma［J］.J Clin Oncol,2007,25(5):579-586.
[8] Cohen JI.Epstein-Barr virus infection［J］.N Engl J Med,2000,343:481-492.
[9] Rezk SA,Weiss LM.Epstein-Barr virus-associated lymphoproliferative disorders［J］.Hum Pathol,2007,38:1293-1304.
[10]Qi Zongli,Zhao Tong,Zhu Meigang.Progress on the relationship between EB virus and hodgkin's lymphoma［J］.Practical Oncology Journal,2002,17(2):221-223.
[11]Wu L,Ehlin-Henriksson B,Zhou X.Epstein-Barr virus(EBV) provides survival factors to EBV+ diffuse large B-cell lymphoma(DLBCL) lines and modulates cytokine induced specific chemotaxis in EBV+ DLBCL［J］.Immunology,2017,12:12792.
[12]Jarrett RF,Stark GL,White J,et al.Scotland and newcastle epidemiology of hodgkin disease study group.Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma:A population-based study［J］.Blood,2005,106(7):2444-24451.
[13]Dupuis J,Emile JF,Mounier N,et al.Groupe d'Etude des Lymphomes de l'Adulte(GELA).Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma,unspecified:A Groupe d'Etude des Lymphomes de l'Adulte(GELA) study［J］.Blood,2006,108(13):4163-4169.
[14] Kenney S,Theodore E.Woodward Award:Development of novel,EBV-targeted therapies for EBV-positive tumors［J］.Trans Am Clin Climatol Assoc,2006,55-73.
[15]Xu Xiaohong,Yang Lei,Tan Qinghe,et al.A modified SMILE regimen for the treatment of extra nodal NK/T cell lymphoma［J］.Modern Oncology,2014,22(6):1438-1440.
[16] Kawaguchi H,Miyashita T,Herbst H,et al.Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome［J］.J Clin Invest，1993,92:1444-1450.
[17] Kikuta H,Sakiyama Y,Matsumoto S,et al.Fatal Epstein-Barr virus-associated hemophagocytic syndrome［J］.Blood，1993,82:3259-3264.
[18] Kikuta H,Taguchi Y,Tomizawa K,et al.Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease［J］.Nature，1988,333:455-457.
[19] O'Dwyer PJ,Leyland-Jones B,Alonso MT,et al.Etoposide(VP-16-213).Current status of an active anticancer drug［J］.N Engl J Med，1985,312:692-700.
[20]Zhou Ying,Cai Qingqing,Lin Xubin,et al.Preliminary clinical report of SMILE regimen in the treatment of relapsed and refractory NK/T cell lymphoma［J］.Journal of Leukemia & Lymphoma,2009,18(4):213-215.
[21]Pan Yaozhu,Bai Hai,Wang Cunbang.Clinical study of autologous hematopoietic stem cell transplantation for the treatment of NK/T cell lymphoma［J］.Modern Oncology,2012,20(5):1025-1027.
[22] Cohen JI,Bollard CM,Khanna R,et al.Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas［J］.Leuk Lymphoma,2008,49(Suppl 1):27-34.
[23] Kanakry JA,Ambinder RF.EBV-related lymphomas:New approaches to treatment［J］.Curr Treat Options Oncol,2013,14(2):224-236.
[24]MaoY，Zhang DW，Zhu H，et al．LMP1 and LMP2a are potential prognostic markers of extra nodal NK/T-cell lymphoma,nasal type(ENKTL)［J］.Diagn Pathol,2012,7:178.
[25] Siddiquey MN,Nakagawa H,Iwata S,et al.Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma［J］.Cancer Sci,2014,105(6):713-722.
[26] U Palendira,AB Rickinson.Primary immunodeficiencies and the control of Epstein-Barr virus infection［J］.Ann N Y Acad Sci,2015,1356:22-44.
[27]Platt CD,Fried AJ,Hoyos-Bachiloglu R,et al.Combined immunodeficiency with EBV positive B cell lymphoma and epidermodysplasia verruciformis due to a novel homozygous mutation in RASGRP1［J］.Clin Immunol,2017,183:142-144.

Memo

Memo:
-
Last Update: 2018-01-29